Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
NF1 mutation
i
Other names:
NFNS, NF1, Neurofibromin 1, Neurofibromatosis-Related Protein NF-1, Truncated Neurofibromin 1
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
4763
Related biomarkers:
Expression
Mutation
CNA
Others
‹
BRAF mutation + NF1 mutation (2)
EGFR mutation + TP53 mutation + NF1 mutation (2)
IDH1 wild-type + NF1 mutation (2)
BRAF G466E + NF1 Y2285fs*5 + NF1 Y2640fs*3 + TP53 D281Y (1)
EGFR exon 20 insertion + NRAS G13V + NF1 R69fs + NF1 S340fs (1)
NF1 2195G>T (1)
NF1 470G>T (1)
NF1 D1644A (1)
NF1 L581Ffs*6 + KRAS A146P + NRAS Q61K + TP53 R175H + PD-L1 T290M (1)
NF1 R2258Q (1)
NF1 R2450X (1)
NF1 rearrangement (1)
NF1 mutation (1)
SDHB mutation + NF1 mutation (1)
NF1 7806+2T>C (0)
NF1 L581Ffs*6 (0)
BRAF mutation + NF1 mutation (2)
EGFR mutation + TP53 mutation + NF1 mutation (2)
IDH1 wild-type + NF1 mutation (2)
BRAF G466E + NF1 Y2285fs*5 + NF1 Y2640fs*3 + TP53 D281Y (1)
EGFR exon 20 insertion + NRAS G13V + NF1 R69fs + NF1 S340fs (1)
NF1 2195G>T (1)
NF1 470G>T (1)
NF1 D1644A (1)
NF1 L581Ffs*6 + KRAS A146P + NRAS Q61K + TP53 R175H + PD-L1 T290M (1)
NF1 R2258Q (1)
NF1 R2450X (1)
NF1 rearrangement (1)
NF1 mutation (1)
SDHB mutation + NF1 mutation (1)
NF1 7806+2T>C (0)
NF1 L581Ffs*6 (0)
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
NF1 mutation
Glioblastoma
NF1 mutation
Glioblastoma
bevacizumab
Sensitive: B - Late Trials
bevacizumab
Sensitive
:
B
bevacizumab
Sensitive: B - Late Trials
bevacizumab
Sensitive
:
B
NF1 mutation
CNS Tumor
NF1 mutation
CNS Tumor
selumetinib
Sensitive: C2 – Inclusion Criteria
selumetinib
Sensitive
:
C2
selumetinib
Sensitive: C2 – Inclusion Criteria
selumetinib
Sensitive
:
C2
NF1 mutation
Glioma
NF1 mutation
Glioma
trametinib
Sensitive: C3 – Early Trials
trametinib
Sensitive
:
C3
trametinib
Sensitive: C3 – Early Trials
trametinib
Sensitive
:
C3
NF1 mutation
Melanoma
NF1 mutation
Melanoma
vemurafenib
Resistant: C3 – Early Trials
vemurafenib
Resistant
:
C3
vemurafenib
Resistant: C3 – Early Trials
vemurafenib
Resistant
:
C3
NF1 mutation
Thyroid Gland Anaplastic Carcinoma
NF1 mutation
Thyroid Gland Anaplastic Carcinoma
atezolizumab + cobimetinib
Sensitive: C3 – Early Trials
atezolizumab + cobimetinib
Sensitive
:
C3
atezolizumab + cobimetinib
Sensitive: C3 – Early Trials
atezolizumab + cobimetinib
Sensitive
:
C3
NF1 mutation
Colorectal Cancer
NF1 mutation
Colorectal Cancer
AZD6738
Sensitive: C3 – Early Trials
AZD6738
Sensitive
:
C3
AZD6738
Sensitive: C3 – Early Trials
AZD6738
Sensitive
:
C3
NF1 mutation
Multiple Myeloma
NF1 mutation
Multiple Myeloma
MEK inhibitor
Sensitive: C3 – Early Trials
MEK inhibitor
Sensitive
:
C3
MEK inhibitor
Sensitive: C3 – Early Trials
MEK inhibitor
Sensitive
:
C3
NF1 mutation
Solid Tumor
NF1 mutation
Solid Tumor
selumetinib
Resistant: C3 – Early Trials
selumetinib
Resistant
:
C3
selumetinib
Resistant: C3 – Early Trials
selumetinib
Resistant
:
C3
NF1 mutation
Melanoma
NF1 mutation
Melanoma
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
NF1 mutation
Melanoma
NF1 mutation
Melanoma
PD1 inhibitor + MEK inhibitor
Sensitive: C3 – Early Trials
PD1 inhibitor + MEK inhibitor
Sensitive
:
C3
PD1 inhibitor + MEK inhibitor
Sensitive: C3 – Early Trials
PD1 inhibitor + MEK inhibitor
Sensitive
:
C3
NF1 mutation
Soft Tissue Sarcoma
NF1 mutation
Soft Tissue Sarcoma
ifosfamide + pegylated liposomal doxorubicin
Resistant: C3 – Early Trials
ifosfamide + pegylated liposomal doxorubicin
Resistant
:
C3
ifosfamide + pegylated liposomal doxorubicin
Resistant: C3 – Early Trials
ifosfamide + pegylated liposomal doxorubicin
Resistant
:
C3
NF1 mutation
Glioblastoma
NF1 mutation
Glioblastoma
trametinib
Sensitive: C3 – Early Trials
trametinib
Sensitive
:
C3
trametinib
Sensitive: C3 – Early Trials
trametinib
Sensitive
:
C3
NF1 mutation
Lung Cancer
NF1 mutation
Lung Cancer
trametinib
Sensitive: C3 – Early Trials
trametinib
Sensitive
:
C3
trametinib
Sensitive: C3 – Early Trials
trametinib
Sensitive
:
C3
NF1 mutation
Glioma
NF1 mutation
Glioma
FCN-159
Sensitive: C3 – Early Trials
FCN-159
Sensitive
:
C3
FCN-159
Sensitive: C3 – Early Trials
FCN-159
Sensitive
:
C3
NF1 mutation
Breast Cancer
NF1 mutation
Breast Cancer
CDK4 inhibitor + CDK6 inhibitor
Resistant: C3 – Early Trials
CDK4 inhibitor + CDK6 inhibitor
Resistant
:
C3
CDK4 inhibitor + CDK6 inhibitor
Resistant: C3 – Early Trials
CDK4 inhibitor + CDK6 inhibitor
Resistant
:
C3
NF1 mutation
Thyroid Gland Medullary Carcinoma
NF1 mutation
Thyroid Gland Medullary Carcinoma
vandetanib
Sensitive: C4 – Case Studies
vandetanib
Sensitive
:
C4
vandetanib
Sensitive: C4 – Case Studies
vandetanib
Sensitive
:
C4
NF1 mutation
Sarcoma
NF1 mutation
Sarcoma
RMC-4630
Sensitive: C4 – Case Studies
RMC-4630
Sensitive
:
C4
RMC-4630
Sensitive: C4 – Case Studies
RMC-4630
Sensitive
:
C4
NF1 mutation
Melanoma
NF1 mutation
Melanoma
VTX-11e
Resistant: D – Preclinical
VTX-11e
Resistant
:
D
VTX-11e
Resistant: D – Preclinical
VTX-11e
Resistant
:
D
NF1 mutation
Melanoma
NF1 mutation
Melanoma
mirdametinib
Sensitive: D – Preclinical
mirdametinib
Sensitive
:
D
mirdametinib
Sensitive: D – Preclinical
mirdametinib
Sensitive
:
D
NF1 mutation
Neurofibrosarcoma
NF1 mutation
Neurofibrosarcoma
DR6MP + JHU395
Sensitive: D – Preclinical
DR6MP + JHU395
Sensitive
:
D
DR6MP + JHU395
Sensitive: D – Preclinical
DR6MP + JHU395
Sensitive
:
D
NF1 mutation
Neurofibrosarcoma
NF1 mutation
Neurofibrosarcoma
DR6MP
Sensitive: D – Preclinical
DR6MP
Sensitive
:
D
DR6MP
Sensitive: D – Preclinical
DR6MP
Sensitive
:
D
NF1 mutation
Neurofibrosarcoma
NF1 mutation
Neurofibrosarcoma
MEK inhibitor + c-MET inhibitor
Sensitive: D – Preclinical
MEK inhibitor + c-MET inhibitor
Sensitive
:
D
MEK inhibitor + c-MET inhibitor
Sensitive: D – Preclinical
MEK inhibitor + c-MET inhibitor
Sensitive
:
D
NF1 mutation
Non Small Cell Lung Cancer
NF1 mutation
Non Small Cell Lung Cancer
ERAS-601
Sensitive: D – Preclinical
ERAS-601
Sensitive
:
D
ERAS-601
Sensitive: D – Preclinical
ERAS-601
Sensitive
:
D
NF1 mutation
Melanoma
NF1 mutation
Melanoma
cobimetinib
Sensitive: D – Preclinical
cobimetinib
Sensitive
:
D
cobimetinib
Sensitive: D – Preclinical
cobimetinib
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login